Yoneda K
Pathology and Laboratory Medicine Service, Veterans Affairs Medical Center, Lexington, Kentucky.
Mod Pathol. 1994 May;7(4):480-6.
Distribution of proliferating-cell nuclear antigen and epidermal growth-factor receptor was studied by immunohistochemistry in intraepithelial squamous cell lesions of human bronchus. Ten biopsy specimens were examined for each of the following categories of lesions (50 specimens altogether): normal bronchial epithelium, benign squamous metaplasia, dysplastic squamous metaplasia, and squamous cell carcinoma in situ, in addition to invasive squamous cell carcinoma. The percentage positivity of immunoreactive cells and their localization in the epithelium were examined in formalin-fixed, paraffin-embedded tissues of bronchial biopsy specimens retrieved from the surgical pathology file. Proliferating-cell nuclear antigen positivity ranged from 3.2% (normal bronchial epithelium), to 7.6% (benign squamous metaplasia), 51.8% (dysplastic squamous metaplasia), and 85.0% (squamous cell carcinoma in situ). The difference between the groups was statistically significant (p < 0.01). The percentage positivity for invasive squamous cell carcinoma was 56.9%. Epidermal growth-factor receptor positivity ranged from 7.3% (normal bronchial epithelium), to 38.7% (benign squamous epithelium), 67.5% (dysplastic squamous metaplasia), and 91.3% (squamous cell carcinoma in situ). The difference between the groups was statistically significant (p < 0.01). Invasive squamous cell carcinoma positivity was 49.7%. Both proliferating-cell nuclear antigen-positive and epidermal growth-factor receptor-positive cells showed zonal distribution in the bronchial epithelium. They were located in the basal cell layer in normal bronchial epithelium and expanded upward as the morphologic changes advanced. In squamous cell carcinoma in situ, both proliferating-cell nuclear antigen-positive and epidermal growth-factor receptor-positive cells covered the entire thickness of the bronchial epithelial layer.(ABSTRACT TRUNCATED AT 250 WORDS)
通过免疫组织化学方法研究了增殖细胞核抗原和表皮生长因子受体在人支气管上皮内鳞状细胞病变中的分布。对以下各类病变的10个活检标本进行了检查（共50个标本）：正常支气管上皮、良性鳞状化生、发育异常的鳞状化生、原位鳞状细胞癌，以及浸润性鳞状细胞癌。在从外科病理档案中获取的支气管活检标本的福尔马林固定、石蜡包埋组织中，检查免疫反应性细胞的阳性百分比及其在上皮中的定位。增殖细胞核抗原阳性率从3.2%（正常支气管上皮）到7.6%（良性鳞状化生）、51.8%（发育异常的鳞状化生）和85.0%（原位鳞状细胞癌）。各组之间的差异具有统计学意义（p<0.01）。浸润性鳞状细胞癌的阳性率为56.9%。表皮生长因子受体阳性率从7.3%（正常支气管上皮）到38.7%（良性鳞状上皮）、67.5%（发育异常的鳞状化生）和91.3%（原位鳞状细胞癌）。各组之间的差异具有统计学意义（p<0.01）。浸润性鳞状细胞癌的阳性率为49.7%。增殖细胞核抗原阳性细胞和表皮生长因子受体阳性细胞在支气管上皮中均呈带状分布。它们位于正常支气管上皮的基底层，并随着形态学变化向上扩展。在原位鳞状细胞癌中，增殖细胞核抗原阳性细胞和表皮生长因子受体阳性细胞均覆盖了支气管上皮层的全层。（摘要截断于250字）
